Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling

Oleksii S. Rukhlenko, Fahimeh Khorsand, Aleksandar Krstic, Jan Rozanc, Leonidas G. Alexopoulos, Nora Rauch, Keesha E. Erickson, William S. Hlavacek, Richard G Posner, Silvia Gómez-Coca, Edina Rosta, Cheree Fitzgibbon, David Matallanas, Jens Rauch, Walter Kolch, Boris N. Kholodenko

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Clinically used RAF inhibitors are ineffective in RAS mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, posttranslational modifications, and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS, and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.

Original languageEnglish (US)
JournalCell Systems
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

MAP Kinase Signaling System
Drug Design
Mitogen-Activated Protein Kinase Kinases
Dimerization
Post Translational Protein Processing
Drug Interactions
Thermodynamics
Phosphotransferases
Cell Proliferation
Neoplasms
Protein Structural Elements

Keywords

  • conformational transitions of the DFG motif and αC helix
  • drug resistance
  • drug synergy
  • MAPK pathway
  • mathematical modeling
  • oncogenic RAS
  • RAF dimerization
  • RAF inhibitors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Cell Biology

Cite this

Rukhlenko, O. S., Khorsand, F., Krstic, A., Rozanc, J., Alexopoulos, L. G., Rauch, N., ... Kholodenko, B. N. (Accepted/In press). Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. Cell Systems. https://doi.org/10.1016/j.cels.2018.06.002

Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. / Rukhlenko, Oleksii S.; Khorsand, Fahimeh; Krstic, Aleksandar; Rozanc, Jan; Alexopoulos, Leonidas G.; Rauch, Nora; Erickson, Keesha E.; Hlavacek, William S.; Posner, Richard G; Gómez-Coca, Silvia; Rosta, Edina; Fitzgibbon, Cheree; Matallanas, David; Rauch, Jens; Kolch, Walter; Kholodenko, Boris N.

In: Cell Systems, 01.01.2018.

Research output: Contribution to journalArticle

Rukhlenko, OS, Khorsand, F, Krstic, A, Rozanc, J, Alexopoulos, LG, Rauch, N, Erickson, KE, Hlavacek, WS, Posner, RG, Gómez-Coca, S, Rosta, E, Fitzgibbon, C, Matallanas, D, Rauch, J, Kolch, W & Kholodenko, BN 2018, 'Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling', Cell Systems. https://doi.org/10.1016/j.cels.2018.06.002
Rukhlenko, Oleksii S. ; Khorsand, Fahimeh ; Krstic, Aleksandar ; Rozanc, Jan ; Alexopoulos, Leonidas G. ; Rauch, Nora ; Erickson, Keesha E. ; Hlavacek, William S. ; Posner, Richard G ; Gómez-Coca, Silvia ; Rosta, Edina ; Fitzgibbon, Cheree ; Matallanas, David ; Rauch, Jens ; Kolch, Walter ; Kholodenko, Boris N. / Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. In: Cell Systems. 2018.
@article{fbb37a5b24c3409698fda87a62b67181,
title = "Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling",
abstract = "Clinically used RAF inhibitors are ineffective in RAS mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, posttranslational modifications, and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS, and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.",
keywords = "conformational transitions of the DFG motif and αC helix, drug resistance, drug synergy, MAPK pathway, mathematical modeling, oncogenic RAS, RAF dimerization, RAF inhibitors",
author = "Rukhlenko, {Oleksii S.} and Fahimeh Khorsand and Aleksandar Krstic and Jan Rozanc and Alexopoulos, {Leonidas G.} and Nora Rauch and Erickson, {Keesha E.} and Hlavacek, {William S.} and Posner, {Richard G} and Silvia G{\'o}mez-Coca and Edina Rosta and Cheree Fitzgibbon and David Matallanas and Jens Rauch and Walter Kolch and Kholodenko, {Boris N.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cels.2018.06.002",
language = "English (US)",
journal = "Cell Systems",
issn = "2405-4712",
publisher = "Cell Press",

}

TY - JOUR

T1 - Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling

AU - Rukhlenko, Oleksii S.

AU - Khorsand, Fahimeh

AU - Krstic, Aleksandar

AU - Rozanc, Jan

AU - Alexopoulos, Leonidas G.

AU - Rauch, Nora

AU - Erickson, Keesha E.

AU - Hlavacek, William S.

AU - Posner, Richard G

AU - Gómez-Coca, Silvia

AU - Rosta, Edina

AU - Fitzgibbon, Cheree

AU - Matallanas, David

AU - Rauch, Jens

AU - Kolch, Walter

AU - Kholodenko, Boris N.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Clinically used RAF inhibitors are ineffective in RAS mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, posttranslational modifications, and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS, and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.

AB - Clinically used RAF inhibitors are ineffective in RAS mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, posttranslational modifications, and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS, and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.

KW - conformational transitions of the DFG motif and αC helix

KW - drug resistance

KW - drug synergy

KW - MAPK pathway

KW - mathematical modeling

KW - oncogenic RAS

KW - RAF dimerization

KW - RAF inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85049352252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049352252&partnerID=8YFLogxK

U2 - 10.1016/j.cels.2018.06.002

DO - 10.1016/j.cels.2018.06.002

M3 - Article

AN - SCOPUS:85049352252

JO - Cell Systems

JF - Cell Systems

SN - 2405-4712

ER -